| HL (n = 295) | LL (n = 221) | P value |
---|---|---|---|
Follow-up time: month (min–max) | 51.2 (8–61) | 51.4 (7–61) | 0.887 |
5-year overall survival rate | |||
All stages | 69.1% | 69.6% | 0.942 |
 Stage I | 91.3% | 85.7% | 0.633 |
 Stage II | 75.9% | 75.0% | 0.955 |
 Stage III | 56.5% | 61.4% | 0.657 |
5-year disease-free survival rate | |||
 All stages | 56.2% | 59.6% | 0.570 |
 Stage I | 77.4% | 80.0% | 0.796 |
 Stage II | 62.1% | 66.7% | 0.512 |
 Stage III | 44.6% | 49.3% | 0.753 |
Loss of follow-up [n (%)] | 32 (10.8) | 21 (9.5) | 0.618 |
Local recurrence [n (%)] | 25 (8.5) | 17 (7.7) | 0.748 |
Tumor metastasis [n (%)] | 118 (40.0) | 85 (38.5) | 0.723 |
Death [n (%)] | 115 (39.0) | 88 (39.8) | 0.848 |